NexGen Medical Systems, Inc. Launches XCOIL® Large Vessel (18mm) Thrombectomy System

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

August 6, 2021

NexGen Medical Systems, Inc., a Minneapolis medical device company, today announced the successful completion of the first human use of their XCOIL® Large Vessel (18mm) Thrombectomy System for the treatment of deep vein thrombosis.

The new device, an expansion of the successful XCOIL® 12mm System, is designed to rapidly remove blood clots in large vessels, such as the iliac vein.

The XCOIL® Thrombectomy Systems are comprised of an Encapsulator sheath and a Retractor catheter. The Retractor is used to engage and extract the clot, pull it into the Encapsulator and remove the clot from the body, while minimizing the need for clot-dissolving lytic drugs.

“This expansion of the XCOIL® platform provides our customers with an effective portfolio of solutions for the many patients suffering from deep vein thrombosis in the United States,” said Denis Harrington, President and Chief Executive Officer of NexGen Medical Systems. “With the successful addition of our Large Vessel solution, NexGen Medical continues to demonstrate our commitment to developing advanced solutions for treating DVT blood clots and in the future expanding our platforms to treat pulmonary embolism clots.”

Dr. David Buechner, MD FSIR, Methodist Hospital, Memphis TN, shared, “Our therapeutic goal is to rapidly restore blood flow by removing the clot, quickly and safely, while minimizing the need for clot-dissolving drugs which are not appropriate for all patients and can have negative side effects. The XCOIL® Thrombectomy System provides a rapid mechanical solution and may improve outcomes, and reduce costs, for our patients.”

Blood clots can cause serious diseases and disorders, including deep vein thrombosis (leg clots), pulmonary embolisms and strokes. DVT occurs when a blood clot forms in the deep veins of the body, typically the legs. Blood clots account for more deaths each year than breast cancer, road traffic accidents, and AIDS combined.

spot_img

DON'T MISS

Related Articles